M A Degli-Esposti

Summary

Affiliation: Immunex Corporation
Country: USA

Publications

  1. ncbi Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
    M A Degli-Esposti
    Department of Biochemistry and the Department of Molecular Biology, Immunex Corporation, Seattle, Washington 98101, USA
    J Exp Med 186:1165-70. 1997
  2. ncbi The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
    M A Degli-Esposti
    Department of Biochemistry, Immunex Corporation, Seattle, Washington 98101, USA
    Immunity 7:813-20. 1997
  3. ncbi TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
    H Walczak
    Immunex Corporation, 51 University Street, Seattle, WA 98101, USA
    EMBO J 16:5386-97. 1997
  4. ncbi Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells
    M A Degli-Esposti
    Department of Biochemistry, Immunex Corporation, Seattle, WA 98101, USA
    J Immunol 158:1756-62. 1997
  5. ncbi New major histocompatibility complex genes
    B Marshall
    Department of Clinical Immunology, Royal Perth Hospital, Western Australia
    Hum Immunol 38:24-9. 1993
  6. ncbi m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection
    E Cretney
    Cellular Immunity Laboratory, The Austin Research Institute, Melbourne, Victoria, Australia
    J Exp Med 190:435-44. 1999

Collaborators

Detail Information

Publications6

  1. ncbi Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
    M A Degli-Esposti
    Department of Biochemistry and the Department of Molecular Biology, Immunex Corporation, Seattle, Washington 98101, USA
    J Exp Med 186:1165-70. 1997
    ..Moreover, unlike TRAIL-R1 and -R2, in a transient overexpression system TRAIL-R3 does not induce apoptosis...
  2. ncbi The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
    M A Degli-Esposti
    Department of Biochemistry, Immunex Corporation, Seattle, Washington 98101, USA
    Immunity 7:813-20. 1997
    ..Like TRAIL-R1 and TRAIL-R2, this receptor shows widespread tissue expression. The human TRAIL-R4 gene has been mapped to chromosome 8p22-21, clustered with three other TRAIL receptors...
  3. ncbi TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
    H Walczak
    Immunex Corporation, 51 University Street, Seattle, WA 98101, USA
    EMBO J 16:5386-97. 1997
    ..The existence of two distinct receptors for the same ligand suggests an unexpected complexity to TRAIL biology, reminiscent of dual receptors for TNF, the canonical member of this family...
  4. ncbi Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells
    M A Degli-Esposti
    Department of Biochemistry, Immunex Corporation, Seattle, WA 98101, USA
    J Immunol 158:1756-62. 1997
    ..These same activities could be induced by membrane-bound and soluble LT beta and LT alpha LT beta oligomers...
  5. ncbi New major histocompatibility complex genes
    B Marshall
    Department of Clinical Immunology, Royal Perth Hospital, Western Australia
    Hum Immunol 38:24-9. 1993
    ..PERB6 was identified by YAC probing of tissue blots, while PERB1 was identified by genomic sequencing...
  6. ncbi m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection
    E Cretney
    Cellular Immunity Laboratory, The Austin Research Institute, Melbourne, Victoria, Australia
    J Exp Med 190:435-44. 1999
    ....